Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Subcutaneous oxyntomodulin reduces body-weight in overweight subjects
ISRCTN ISRCTN33638415
ClinicalTrials.gov identifier
Public title Subcutaneous oxyntomodulin reduces body-weight in overweight subjects
Scientific title
Acronym N/A
Serial number at source 071446
Study hypothesis The effect of self-administered subcutaneous oxyntomodulin on overweight volunteers was investigated in a four week community-based study. We hypothesised oxyntomodulin would reduce body weight and appetite.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Obesity
Participants - inclusion criteria 1. Healthy male and female volunteers, aged 18 to 55 years
2. A stable Body Mass Index (BMI) between 25 and 40 kg/m^2
Participants - exclusion criteria 1. Abnormal eating behaviour
2. A current medical condition
3. Abnormal ElectroCardioGram (ECG)
4. Abnormal blood tests
5. Pregnancy or breast-feeding
6. Blood donation or participation in another research study within the last three months
Anticipated start date 02/01/2004
Anticipated end date 31/08/2004
Status of trial Completed
Patient information material
Target number of participants 26 - recruitment ends on the 1st July 2004
Interventions Healthy overweight volunteers self-administered either saline or oxyntomodulin subcutaneously for four weeks, three times daily, 30 minutes before each meal, in a randomised double-blind parallel-group protocol. The volunteers were asked to maintain their regular diet and level of physical exercise. Subjects' body weight, energy intake and levels of adipose hormones were assessed at the start and end of the study.
Primary outcome measure(s) Body weight, energy intake and adipose hormones.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding The Wellcome Trust (UK) (grant ref: 071446)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/16046306
Contact name Prof  S R  Bloom
  Address Hammersmith Hospital
Commonwealth Building
Department of Metabolic Medicine
Du Cane Road
  City/town London
  Zip/Postcode W12 0NN
  Country United Kingdom
  Tel +44 (0)20 8383 3242
  Fax +44 (0)20 8383 3142
  Email s.bloom@imperial.ac.uk
Sponsor Imperial College London (UK)
  Address Level 2, Faculty Building
Clinical Research Office
South Kensington campus
  City/town London
  Zip/Postcode SW7 2AZ
  Country United Kingdom
  Email clinical.researchoffice@imperial.ac.uk
Date applied 22/07/2005
Last edited 04/08/2008
Date ISRCTN assigned 22/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central